Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 in pretreated metastatic NSCLC with activated PI3K pathway
NL-OMON38313Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of buparlisib in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started Oct 2011; status: recruiting.
02
Drugs
buparlisib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON38313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38313.